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Autosomal dominant polycystic kidney disease (ADPKD)
is the most frequent inherited nephropathy, with an esti-
mated prevalence of 1:1000. The disease is characterized
by the development of multiple cysts from all nephron
segments leading to the enlargement of both kidneys and
replacement of normal parenchyma (see [1]). Change in
total kidney volume over time is the strongest predictor
of renal function decline in ADPKD [2]. Glomerular filtra-
tion rate remains preserved up to the age of 40 years in most
patients because glomerular hyperfiltration in functioning
nephrons compensates for the ongoing loss of renal tissue,
until end-stage renal failure ensues in >50% of patients,
usually in their fifth decade. Mutations in the PKD1 gene
account for ~85% of the affected families, whereas the
remaining cases are caused by mutations in PKD2. PKD1
encodes polycystin-1, an integral membrane protein with a
large extracellular domain that probably functions as a re-
ceptor and/or an adhesion molecule, whereas PKD2 enco-
des polycystin-2, a non-selective cation channel belonging
to the family of transient receptor potential channels. The
polycystins are located in the primary cilium and interact to
form a mechanosensory complex that is involved in intra-
cellular Ca21 homeostasis and various signalling pathways.
Disruption of the complex leads to cyst development and
enlargement resulting from tubular cell proliferation and
transepithelial fluid secretion. The progressive understand-
ing of these pathways has led to spectacular advances in the
prospective treatment for ADPKD, including the blockade
of vasopressin 2 receptor (V2R) to decrease the intracellu-
lar level of 3#-5#-cyclic adenosine monophosphate (cAMP)
in cyst-lining tubular cells [1].
Vasopressin and cAMP in ADPKD
The V2R is the major regulator of adenylyl cyclase activity
and of cAMP production in the principal cells of the
collecting ducts. Increased levels of cAMP and high ex-
pression of cAMP target genes have been observed in the
cystic kidneys of various rodent models. These changes
could arise from decreased intracellular Ca21 concentration
caused by mutations in polycystins 1/2, via the down-reg-
ulation of phosphodiesterase and stimulation of the Ca21
inhibitable adenylyl cyclase 6 [1]. In turn, the increased
production of cAMP stimulates proliferation and growth
of ADPKD cells and drives Cl and fluid secretion via
protein kinase A-stimulated CFTR and, potentially, other
transport processes located in the apical and basolateral
membranes [3].
The importance of the V2R–cAMP pathway has been
demonstrated by the spectacular effects of the V2R antag-
onists (V2RA) OPC-31260 and OPC-41061 (Tolvaptan)
on lowering renal cAMP levels, slowing renal cyst growth
and improving renal function in various models of autoso-
mal recessive (PCK rat) and autosomal dominant
(Pkd2WS25/ mouse) polycystic kidney disease [4]. Similar
protection has been observed when vasopressin secretion is
inhibited by high water intake in PCK rats [5]. Further-
more, the deletion of vasopressin in these PCK rats (by
crossing them to Brattleboro rats) led to lower renal cAMP
levels and an almost complete inhibition of cystogenesis,
whereas administration of dDAVP recovered the cystic
phenotype [6]. Based on these pre-clinical studies, a Phase
III clinical trial investigating the effect of Tolvaptan in
ADPKD patients (TEMPO 3/4) has been initiated in
2007 [7]. This trial enrolled >1400 ADPKD patients with
relatively preserved kidney function (baseline estimated
creatinine clearance 60 mL/min), aged 50 years or
younger and with total kidney volume 750 mL
(magnetic resonance imaging measurement). Blockade
of V2R is hypothesized to inhibit cyst growth, thereby
delaying ADPKD-associated complications including
kidney function decrease, blood pressure control and flank
pain.
V2RA in Pkd1 mice
The aim of the TEMPO 3/4 trial is to examine whether
tolvaptan at a high dose is able to slow renal cystic
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progression in a pre-selected ADPKD population at a rel-
atively early stage of disease and with a risk of progression
to kidney failure. Independent of the final study outcome,
this trial will leave important questions open, in particular
the potential interest of V2RA for patients with more ad-
vanced disease and their efficacy at lower doses which
should decrease the side effects (polyuria and nycturia)
and thus improve tolerance. The investigations performed
in a Pkd1 mouse model by Meijer et al. [8] provide inter-
esting insights into these issues. The study is based on the
oral administration of OPC-31260 at a high (0.1% w/w in
ground rodent chow) or low (0.05%) dose, 10 days after the
specific deletion of Pkd1 in renal tubular epithelium in 11-
day old mice (using a tamoxifen-inducible Cre system).
After a 3-week or 6-week treatment (late versus early in-
tervention, respectively), the mice were sacrificed and
sampled to monitor renal function parameters and kidney
cyst growth.
The first finding is that an early (starting at 3 weeks of
age) and short-term (3 weeks) treatment of this Pkd1
mouse model with high dose of V2RA resulted in a
significant aquaretic effect and attenuation of the renal
cystic phenotype (estimated by relative cyst area and
kidney weight) as compared with untreated Pkd1-deleted
mice. These results confirm some of the V2RA effects
observed in other polycystic mouse models [4], although
the treatment did not ameliorate renal function and was
not shown to lower cAMP levels and decrease the expres-
sion of target genes in this Pkd1 model [8]. Secondly, the
protective effect on the renal cystic phenotype is no
longer observed after long-term (6 weeks) administration
of the V2RA, even at a high dose. This treatment escape is
parallelled by a lower aquaretic response to the V2RA, as
attested by less marked changes in the urinary volume,
urinary osmolality and water intake parameters at Week 6
versus Week 3. It must be noted that the intake of V2RA
remained similar between the two time points, whereas
the messenger RNA (mRNA) expression of V2R was
significantly decreased at Week 6. The third finding of
the study is the fact that administration of V2RA at a more
advanced stage of disease (6 weeks of age, late interven-
tion) induced a lower aquaretic response and showed no
effect on cyst growth. Based on these findings, the
authors conclude that intervention with V2RA should
be initiated early in the course of the disease, at high dose,
and that combination therapy may be needed to reduce
cystogenesis at a later stage.
From Pkd1 mice to ADPKD patients
The results of Meijer et al. [8] raise several points regard-
ing the translation of animal study results to human
ADPKD. The discordance between encouraging pre-clin-
ical studies and disappointing results of two clinical trials
using mTOR inhibitors [9, 10] has pointed to issues such
as drug dosage, time of treatment initiation, duration of
administration, choice of end-point and surrogate markers
and, most importantly, relevance of the pre-clinical mod-
els used to test drugs and predict human outcomes [11].
The mouse model used by Meijer et al. arises from the
deletion of the Pkd1 gene (orthologous to human PKD1)
in the mouse. However, the kidney-specific loss of Pkd1
occurs at once, in the early postnatal phase, and it is seg-
ment-specific, reflecting the expression of Cre recombi-
nase [8]. These characteristics are very different from the
two-hit model, which remains the most commonly accep-
ted explanation for the focal and clonal nature of cysto-
genesis in human ADPKD [1]. Elegant studies have also
demonstrated that the very timing of Pkd1 inactivation
plays a major role in the cystogenesis profile in mouse
models [12]. These factors probably explain the signifi-
cant phenotype variations observed in different models.
For instance, the Pkd1 mice used by Meijer et al. show a
majority of cysts stained for uromodulin, a specific marker
of the thick ascending limb of Henle’s loop [13], whereas
only 20% of cysts, generally smaller, are positive for
aquaporin-2 (AQP2), and no cysts positive for proximal
tubule markers [8]. This profile is clearly distinct from
what is observed in other models of Pkd1 or Pkd2 inacti-
vation [14, 15]. In human ADPKD, Bachinsky et al. [16]
located AQP1 in a majority (~70%) of cysts of proximal
tubule origin (gp330 positive), whereas a minority of the
cysts, negative for AQP1 and gp330, expressed AQP2. De-
vuyst et al. [17] confirmed the selective and mutually exclu-
sive expression of AQP1 and AQP2 in various stages of
ADPKD. In end-stage ADPKD, two-thirds of the cysts ex-
pressed either AQP1 or AQP2, but the two water channels
never co-localized in the same cyst. Of note, the proportion
of AQP2-positive cysts significantly increased with cyst size,
supporting a role for vasopressin in cyst enlargement [17].
An intriguing observation made by Meijer et al. is the
decreased efficacy of the high-dose V2RA over time, with
no significant protection observed after 6-week treatment.
The authors show that this is not due to a lower intake of
the drug (as estimated by food intake), nor to increased
endogenous vasopressin levels (as estimated from un-
changed co-peptin precursor) and the global mRNA ex-
pression of the V2R was actually lower at this stage [8].
Differences in pharmacokinetics and timing and/or insuf-
ficient inhibition of the V2R in this model constitute a
potential explanation. Indeed, significant effects on renal
cystogenesis and function were observed in the Pkd2
mouse model after 12 weeks of treatment with 0.05%
OPC31260 [15]. Changes in downstream effectors of vas-
opressin action in the collecting duct cells, which can be
affected by polycystin-1 dosage, could also play a role
[18]. Another hypothesis would be that the extent of the
V1a receptor (V1aR) antagonistic effect on V2R signalling,
which could contribute to the initial aquaretic effect of the
V2RA, could decrease over time (due to e.g. the progressive
down-regulation of V1aR) [19]. These findings may also sug-
gest that the timing of Pkd1 inactivation in this model triggers
cystogenesis via temporally and spatially distinct pathways in
different tubular segments so that the effect of V2R blockage
on cysts arising from the collecting ducts may only be partial
and limited in time. If proved true, this mechanism of cysto-
genesis would necessitate combining various drugs targeting
these segment-specific pathways of cystogenesis.
Two final considerations should be made when extrap-
olating these mouse studies to man. Firstly, the timing of
intervention (treatment started at 3 weeks of age in the early
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intervention group) is in fact very early when considering
that significant changes in renal tubular maturation occur
up to 6–8 weeks of age in mouse [20, 21]. In man, such an
early intervention would mean to treat young children, with
potential long-term consequences due to among others,
prolonged polyuria [22]. Secondly, there are species differ-
ences in the functional effect of vasopressin in the distal
nephron (thick ascending limbs and collecting ducts),
which probably sustain the much higher urinary concen-
trating capacity of the rodents as compared to man [23].
The latter is explained by considerable differences in both
renal anatomy (e.g. proportionally much longer loops of
Henle in the inner medulla and papilla of the mouse) and
metabolic rate (much larger amount of osmoles needed to
be excreted in mouse). Furthermore, the segmental distri-
bution of the V2 receptors in mouse and human kidneys
remains debated [24, 25]. The effect of V2R blockade in
any rodent model should thus be interpreted carefully in
view of these potential differences.
Conclusions
Since cyst expansion is a major factor for the progressive
deterioration and loss of renal function in ADPKD,
therapies targeting fluid secretion and, thereby, cyst en-
largement are of major clinical interest. The study of Meijer
et al. [8] provides further support for the effect of V2RA on
slowing cyst growth in ADPKD, shown for the first time in
a PKD1 orthologous model. Although this effect is not
reflected by protection in terms of renal function and fib-
rosis in this model, these findings suggest that the V2RA
treatment should be initiated very early in the disease and
with a high dose inducing a strong aquaretic effect. The fact
that V2RA effect is not sustained supports the view that
cystogenesis may be a dynamic process involving different
segments during the disease course. Moreover, these results
emphasize the need for better characterization of disease
mechanisms and species differences when considering the
pre-clinical models used to investigate new therapeutic
targets.
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